Alex  Leech

Alex is a Partner in the Sofinnova Biovelocita Strategy. He is an experienced biopharma company builder and a serial CEO, most recently serving as the founding CEO of Alchemab Therapeutics, which raised an $82m Series A investment round.

He was CEO of the clinical stage dermatology company Creabilis Therapeutics until its acquisition by Sienna Biopharmaceuticals Inc. in 2016.

“Sofinnova's Biovelocita Strategy is a perfect fit for me," Alex said. "Together, we expect to build an exciting portfolio of leading biotechnology companies from cutting-edge European science."

Alex's other company-building roles include serving as CEO of Camphos and Zarodex, Entrepreneur in Residence at Bicycle Tx, and as a Venture Partner with SV Health Investors in London. He is currently Chair of the Board at two start-ups, Ensocell and Sevenless.

He previously held a range of senior project management positions within Pfizer's R&D organization, including working as part of a small team leading the restructuring of Pfizer’s drug development capabilities.

Early in his career, Alex gained valuable management and commercial experience at Ford Motor Company and the Visteon Corporation. He holds a BEng in Mechanical Engineering from the University of Sussex and an MBA from Henley Management College, UK.